Larimar Therapeutics (LRMR) Price & Analysis

Compare

868 Followers

LRMR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.61 - $9.50

Previous CloseN/A

Volume147.46K

Average Volume (3M)1.67M

Market Cap

$307.11M

Enterprise Value$51.13M

Total Cash (Recent Filing)$138.52M

Total Debt (Recent Filing)$4.61M

Price to Earnings (P/E)―

Beta2.15

Next Earnings

Nov 18, 2025

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding82,777,890

10 Day Avg. Volume1,337,713

30 Day Avg. Volume1,666,024

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.17

Enterprise Value/Revenue106.08

Enterprise Value/Gross Profit-6.39K

Enterprise Value/Ebitda-0.47

Forecast

1Y Price Target

$19.75

Price Target Upside410.34% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Accelerated Approval PathwayFDA has communicated that frataxin concentrations in skin could serve as the basis for accelerated approval, supporting Larimar's pathway for approval.

Financial PerformanceLarimar raised an additional $65.1M, lifting cash to $203.6M, which extends its financial runway.

Regulatory ProgressThe Ph3 trial for nomlabofusp is on track to begin enrollment with a study design accepted by both FDA and EMA, emphasizing a rigorous and approved approach.

Bears Say

Clinical Trial RequirementsThe company needs to evaluate safety data from at least 30 participants with continuous study drug exposure for six months to support the regulatory submission.

Safety And Efficacy DataFunctional data alongside FXN expression and an acceptable safety profile is needed to support a favorable risk/benefit for nomlabofusp to receive accelerated approval.

Study Enrollment ChallengesParticipants from the 25 mg cohort were switched to 50 mg and are expected to complete a year of continuous dosing prior to BLA submission.

Larimar Therapeutics News

3 Best Stocks to Buy Now, 9/1/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

5d ago

APLD

LRMR

3 Best Stocks to Buy Now, 8/15/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

22d ago

CMG

LRMR

Larimar Therapeutics price target lowered to $18 from $22 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Larimar Therapeutics (LRMR) to $18 from $22...

22d ago

LRMR

Larimar Therapeutics reports Q2 EPS (41c), consensus (49c)

“We are pleased with our continued strong execution as we further advance our nomlabofusp program towards potential registration....

23d ago

LRMR

Promising Developments and Strategic Timeline Drive Buy Rating for Larimar Therapeutics

William Blair analyst Myles Minter has maintained their bullish stance on LRMR stock, giving a Buy rating on...

8d ago

LRMR

Positive Outlook for Larimar Therapeutics: Buy Rating Supported by FDA Decisions and Upcoming Trial Data

Leerink Partners analyst Joori Park has reiterated their bullish stance on LRMR stock, giving a Buy rating on...

15d ago

LRMR

Buy Rating for Larimar Therapeutics: Strong Phase 3 Progress, Regulatory Alignment, and Market Advantage

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Larimar Therapeutics. The associated price target remains...

17d ago

LRMR

Promising Advancements and Strategic Positioning Drive Buy Rating for Larimar Therapeutics

In a report released yesterday, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Larimar Therapeutics,...

22d ago

LRMR

Larimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses

Larimar Therapeutics, Inc. ( ($LRMR) ) has released its Q2 earnings. Here is a breakdown of the information...

22d ago

LRMR

Promising Data and Optimistic Outlook Drive Buy Rating for Larimar Therapeutics

William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating on...

23d ago

LRMR

Larimar Therapeutics Reports Q2 2025 Financial Results

Larimar Therapeutics ( ($LRMR) ) has issued an announcement. On August 14, 2025, Larimar Therapeutics reported its second...

23d ago

LRMR

Larimar Therapeutics Announces $64.4 Million Stock Offering

Larimar Therapeutics ( ($LRMR) ) has provided an update. On July 29, 2025, Larimar Therapeutics, Inc. entered into...

1M ago

LRMR

Larimar Therapeutics 18.75M share Spot Secondary priced at $3.20

The deal priced at low end of $3.20-$3.40 range. Leerink and Guggenheim are acting as joint book running...

1M ago

LRMR

Larimar Therapeutics TBA Spot Secondary; price range $3.20-$3.40

Leerink and Guggenheim are acting as joint book running managers for the offering. Published first on TheFly –...

1M ago

LRMR

LRMR FAQ

What was Larimar Therapeutics, Inc.’s price range in the past 12 months?

Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $9.50 in the past 12 months.

What is Larimar Therapeutics, Inc.’s market cap?

Larimar Therapeutics, Inc.’s market cap is $307.11M.

When is Larimar Therapeutics, Inc.’s upcoming earnings report date?

Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.

How were Larimar Therapeutics, Inc.’s earnings last quarter?

Larimar Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.48 by $0.07.

Is Larimar Therapeutics, Inc. overvalued?

According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Larimar Therapeutics, Inc. pay dividends?

Larimar Therapeutics, Inc. does not currently pay dividends.

What is Larimar Therapeutics, Inc.’s EPS estimate?

Larimar Therapeutics, Inc.’s EPS estimate is -0.41.

How many shares outstanding does Larimar Therapeutics, Inc. have?

Larimar Therapeutics, Inc. has 82,777,890 shares outstanding.

What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?

Larimar Therapeutics, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.48. Following the earnings report the stock price went up 14.516%.

Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?

Currently, no hedge funds are holding shares in LRMR

Larimar Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-60.25%

Trailing 12-Months

Asset Growth

-36.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics (LRMR) Earnings & Revenues

Historic Earnings Reports

LRMR Stock 12 Month Forecast

Average Price Target

$19.75

▲(410.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","34":"$34","9.25":"$9.25","17.5":"$17.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.25,17.5,25.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,5.713846153846154,7.987692307692308,10.26153846153846,12.535384615384615,14.80923076923077,17.083076923076923,19.356923076923078,21.630769230769232,23.904615384615386,26.17846153846154,28.452307692307695,30.726153846153846,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,4.694615384615385,5.949230769230769,7.203846153846154,8.458461538461538,9.713076923076922,10.967692307692307,12.222307692307691,13.476923076923075,14.73153846153846,15.986153846153844,17.240769230769228,18.495384615384616,{"y":19.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,3.9446153846153846,4.44923076923077,4.953846153846154,5.458461538461538,5.963076923076923,6.4676923076923085,6.972307692307693,7.476923076923077,7.981538461538461,8.486153846153847,8.990769230769232,9.495384615384616,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >